The FINANCIAL -- Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company announced the U.S. Food and Drug Administration has approved Jentadueto tablets, a new tablet combining the dipeptidyl peptidase-4 inhibitor, linagliptin, and metformin, according to Eli Lilly and Company.

JENTADUETO provides a new, single-tablet treatment option, taken twice-daily, for patients who need to control their blood sugar. Linagliptin is marketed in the U.S. as Tradjenta tablets.

JENTADUETO is a prescription medication used along with diet and exercise to improve glycemic control in adults with type 2 diabetes when treatment with both linagliptin and metformin is appropriate. At the maximum dose, JENTADUETO demonstrated placebo-corrected reductions in hemoglobin A levels of up to 1.7 percent.

A1C is measured in people with diabetes to provide an index of blood sugar control for the previous two to three months. JENTADUETO did not cause any meaningful change in body weight. JENTADUETO can be used alone or in combination with a sulfonylurea, a commonly prescribed medication for type 2 diabetes. JENTADUETO is not for the treatment of type 1 diabetes or diabetic ketoacidosis. It has not been studied in combination with insulin.

The JENTADUETO label contains a boxed warning for the risk of lactic acidosis, a serious metabolic complication that can occur due to metformin accumulation during treatment with JENTADUETO.

Related Stories

• FDA Advisory Committee Finds Data Support Effectiveness of Tafamidis Meglumine
• Pfizer Names Olivier Brandicourt as President and General Manager
• Janssen Healthcare Innovation Announces Discharge Decision Support System Winner